The inhibition of p300-dependent acetylation of GATA4 suppresses the transcription of cardiac hypertrophic response genes, cardiomyocyte hypertrophy, and the development of heart failure, suggesting that regulation of the transcriptional activity of GATA4 could serve as a novel therapeutic strategy for heart failure 11, 12. The gene discussed is EP300; the disease is heart failure.